Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2020-08
  • 2020-07
  • 2018-07
  • br Author contributions br The manuscript was written

    2022-09-07


    Author contributions
    The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. The authors declare no conflict of interests.
    R. Domínguez-Ríos, et al.
    Acknowledgement
    The authors thank CONACYT-SEP Basic Science fund (research project ID: 23750).
    Appendix A. Supplementary data
    References
    C. Sessa, C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO
    C. Alvarez-Lorenzo, A. Concheiro, P. Taboada, V. Mosquera, Poly(styrene oxide)-poly(ethylene oxide) block copolymers: from “classical” chemotherapeutic nano-carriers to active cell-response inducers, J. Control. Release 167 (2013) 68–75,
    R. Domínguez-Ríos, et al.
    P. Gunasekaran, K. Muthuchelian, S. Kannan, Multifunctional HER2-Antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-re-sistant breast cancer therapy, ACS Appl. Mater. Interfaces 6 (2014) 6469–6480, https://doi.org/10.1021/am406012g.
    F. Pettinella, A. Masserdotti, F. Riccio, A. Bianchi, L. Zammataro, C. Haydu,
    [51] M.A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, J. Baselga, Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits asal and activated HER2 ectodomain cleavage in breast cancer cells, Cancer Res. 61 (2001) 4744–4749.
    207 Accepted Manuscript
    CIZ1 knockdown suppresses the proliferation of Adriamycin cancer cells by inducing apoptosis
    Xiaosong Chen, Ping Wang, Shenghan Wang, Jin Li, Tongwen Ou, Xiaoyong Zeng
    This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    ACCEPTED MANUSCRIPT
    CIZ1 knockdown suppresses the proliferation of bladder cancer cells by inducing
    apoptosis
    1, Department of Urology, Xuanwu Hospital of The Capital Medical University, Xuanwu
    Hospital, No.45,Changchun Street, Xicheng district, Beijing, P. R. China.
    2,General Practice, Beijing Xicheng District White Paper Community Health Service Center,
    No.4 Xinan Zhongli, Xicheng district, Beijing, P. R. China.
    3, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of
    #, These authors contributed equally to this work.
    *Correspondence to: XiaoyongZeng, MD, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095, liberation avenue, Wuhan, 430030, Hubei, P. R. China. Telephone: +86-27-83662688, Fax:
    ACCEPTED MANUSCRIPT
    Abstract
    Bladder cancer (BC) is the ninth most frequent malignancy and the thirteenth leading cause of cancer-related death worldwide. CDKN1A-interacting zinc finger protein 1 (CIZ1) is involved in the development of various cancers, while its role in BC remains unclear. In this study, we found that CIZ1 was up-regulated in BC tissues and cells. Knockdown of CIZ1 suppressed the proliferation and growth of T24 and 5637 cells. Apoptosis and caspase 3/7 activity were enhanced after CIZ1 silencing in both cells. At the molecular level, PCNA, Ki67, HIF-1α, survivin, CCND1 and CCNB1 were down-regulated, and caspase-3, p53, p21, caspase-9 were up-regulated by CIZ1 knockdown. This suggested that silencing of CIZ1 suppressed BC cell proliferation through inducing apoptosis and reducing cell cycle progression. Our study suggests that targeting CIZ1 maybe a potential therapeutic strategy for BC.
    Keywords: bladder cancer, CIZ1, cell proliferation, apoptosis